CoChat
Sign Up
Cited by 36Glioma Diagnosis and TreatmentCancer Cells and MetastasisAngiogenesis and VEGF in Cancer

CD133 Expression in Glioblastoma Multiforme: A Literature Review

Open access
Ahmed, Syed Ijlal, Javed, Gohar, Laghari, Altaf Ali, Bareeqa, Syeda Beenish, Farrukh, Saba, Zahid, Shajeeah, Samar, Syeda Sana, Aziz, Kashif·2018·Cureus
DOI 10.7759/cureus.3439PMC PMC6290980
Open this paper in CoChat — free accountOpen PDF

Abstract

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most common primary brain tumor. Extensive research has been carried out to discover the factors associated with the course and progression of GBM. CD133 is a glycoprotein antigen found in normal and malignant tissues. CD133 has been recognized as a marker for the growth of cancer cells. The association between this tissue marker and GBM is being investigated. The aim of this review was to evaluate the role of CD133 as a tumor marker for the prognosis of GBM.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7759/cureus.3439

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Serum can be a source of microRNAs as they can pass through the blood-brain barrier and remain stable in the blood.

    “Serum can be a source of microRNAs as they can pass through the blood-brain barrier and remain stable in the blood [36].”

    From miR-21 as a diagnostic and prognostic biomarker in glioma: tissue and serum expression analysis in a Pakistani cohort (2026) · cites this paper as [36]

    The Introduction and Review discuss CD133 expression in glioblastoma, including mRNA levels and shRNA-mediated suppression, but do not address serum microRNAs. Searches for microRNAs crossing the blood-brain barrier and for circulating serum biomarkers found no passage supporting the claim. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 29

  1. [1]An integrated genomic analysis of human glioblastoma multiforme Science Parsons DW Jones S Zhang X 1807 1812 Science 321 2008 18772396 PMC2820389
  2. [2]CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010 Neuro Oncol Ostrom QT Gittleman H Farah P 1 56 15 2013 24137015 PMC3798196
  3. [3]A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999 Cancer Chakrabarti I Cockburn M Cozen W Wang YP Preston-Martin S 2798 2806 104 2005 16288487
  4. [4]Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006 Neuro Oncol Yabroff KR Harlan L Zeruto C Abrams J Mann B 351 359 14 2012 22241797 PMC3280803
  5. [5]Stem cells, cancer, and cancer stem cells Nature Reya T Morrison SJ Clarke MF Weissman IL 105 111 414 2001 11689955
  6. [6]Cancer stem cells in nervous system tumors Oncogene Singh SK Clarke ID Hide T Dirks PB 7267 7273 23 2004 15378086
  7. [7]Cancer stem cells: lessons from leukemia Trends Cell Biol Wang JC Dick JE 494 501 15 2005 16084092
  8. [8]Self-renewal and solid tumor stem cells Oncogene Al-Hajj M Clarke MF 7274 7282 23 2004 15378087
  9. [9]Applying the principles of stem-cell biology to cancer Nat Rev Cancer Pardal R Clarke MF Morrison SJ 895 902 3 2003 14737120
  10. [10]Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma Mol Cancer Liu G Yuan X Zeng Z 67 5 2006 17140455 PMC1697823
  11. [11]CD133: a stem cell biomarker and beyond Exp Hematol Oncol Li Z 17 2 2013 23815814 PMC3701589
  12. [12]Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin Cancer Res Lottaz C Beier D Meyer K 2030 2040 70 2010 20145155
  13. [13]CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer J Gastrointest Oncol Lim SH Jang J Park JO 447 456 5 2014 25436124 PMC4226826
  14. [14]A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations Proc Natl Acad Sci U S A Yan X Ma L Yi D 1591 1596 108 2011 21220328 PMC3029739
  15. [15]Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer Gastric Cancer Hashimoto K Aoyagi K Isobe T Kouhuji K Shirouzu K 97 106 17 2014 23558457 PMC3889295
  16. [16]AC133, a novel marker for human hematopoietic stem and progenitor cells Blood Yin AH Miraglia S Zanjani ED 5002 5012 90 1997 http://www.bloodjournal.org/content/90/12/5002 9389720
  17. [17]The stem cell-associated antigen CD133 (prominin-1) is a molecular therapeutic target for metastatic melanoma Stem Cells Rappa G Fodstad O Lorico A 3008 3017 26 2008 18802032 PMC2713505
  18. [18]Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody Nanomedicine Wang CH Chiou SH Chou CP Chen YC Huang YJ Peng CA 69 79 7 2011 20620237
  19. [19]Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria Oncogene Günther HS Schmidt NO Phillips HS 2897 2909 27 2008 18037961
  20. [20]Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas Lab Invest Joo KM Kim SY Jin X 808 815 88 2008 18560366
  21. [21]CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells Int J Cancer Wang J Sakariassen PØ Tsinkalovsky O 761 768 122 2008 17955491
  22. [22]Identification of human brain tumour initiating cells Nature Singh SK Hawkins C Clarke ID 396 401 432 2004 15549107
  23. [23]CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles Cancer Res Beier D Hau P Proescholdt M 4010 4015 67 2007 17483311
  24. [24]Neural stem cell isolation and characterization Methods Enzymol Rietze RL Reynolds BA 3 23 419 2006 17141049
  25. [25]Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma Cancer Res Galli R Binda E Orfanelli U 7011 7021 64 2004 15466194
  26. [26]High CD133 expression is associated with worse prognosis in patients with glioblastoma Mol Neurobiol Zhang W Chen H Lv S Yang H 2354 2360 53 2016 25983032
  27. [27]Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles—a role of the endocytic-exocytic pathway EMBO Mol Med Bauer N Wilsch-Bräuninger M Karbanová J 398 409 3 2011 21591261 PMC3210830
  28. [28]Expression and regulation of AC133 and CD133 in glioblastoma Glia Campos B Zeng L Daotrong PH Eckstein V Unterberg A Mairbäurl H Herold-Mende C 1974 1986 59 2011 21901757
  29. [29]A hierarchy of self-renewing tumor-initiating cell types in glioblastoma Cancer Cell Chen R Nishimura MC Bumbaca SM 362 375 17 2010 20385361

Cited by

Sorted by citations

Authors
Ahmed, S. I., Javed, G., Laghari, A. A., Bareeqa, S. B., Farrukh, S., Zahid, S., Samar, S. S., & Aziz, K.
Affiliations
Aga Khan University (PK)
Corresponding author
Ahmed, Syed Ijlal
ORCID
Venue
Cureus
Publisher
Springer Science and Business Media LLC
Published
2018-10-11
Volume
10
Issue
10
Pages
e3439-e3439
ISSN
2168-8184 (ISSN-L)
DOI
10.7759/cureus.3439
PMC
PMC6290980
OpenAlex
W2895913993
Cited by
36
References
0
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 7 · 2021: 7 · 2020: 5 · 2019: 3
FWCI
2.13
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cureus (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eCommons - AKU (Aga Khan University) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
CD133, glioblastoma, tumor markers, prognosis, glycoprotein antigen, cancer stem cells, primary brain tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review